Table 3. Characteristics of Included Studies for the 30-Day Post-Stent Thrombosis Mortality and Myocardial Infarction Meta-Analyses.
| Author, Year (N STs) | Data Recording | Inclusion Criteria | Stent Type | Country of Conduct | Inclusion Years | Definition of ST | Timing of ST | APT at ST Diagnosis | Funding |
|---|---|---|---|---|---|---|---|---|---|
| Becker 2009 (N=47) | P | Patients experiencing STEMI as a consequence of ST | Both DES and BMS; % NR | 1 center in Hungary | 2003-2005 | Definite | AST= 11%; SAST/LST=89% | CLO/TIC=90%;ASA=87% | NR |
| Burzotta 2008 (OPTIMIST) (N=110) | P/R | Any patient with angiographically confirmed ST, resting angina or new ischemic ECG changes or cardiac biomarker elevations (73% STEMI at presentation) | BMS=50%; DES=39%; Unknown=11% | 11 centers in Italy | 2005-2006 | Definite | EST=72%; LST=20%; VLST=8% | NR | Unfunded |
| Cheneau 2003 (N=27*) | P | Patients experiencing SAST within 7 days of IVUS-guided stent implantation (excluded MI within 1 month of intervention) | BMS=100% | 1 center in the United States | 1993-2002 | Recurrent ischemia and documented stented vessel occlusion within 7 days of index PCI | SAST=100% | DAPT=100% | NR |
| Dannenberg 2009 (N=29) | I | Patients who underwent angioplasty and were readmitted with a diagnosis of ST (53% MI at presentation) | DES=25%; BMS=75% | 1 center in Israel | 2004-2006 | Definite | Between 2 days and 3 years after ST; LST=10% | CLO=38%; ASA=66% | NR |
| Heestermans 2010 (N=201) | I | Consecutive patients stented for STEMI and presenting with ST | BMS=28%; DES=70%; Unknown=2% | 3 centers in the Netherlands | 2004-2007 | Definite | AST=48%; SAST=52% | CLO=78% | NR |
| Kuchulakanti 2006 (N=38) | P | All patients treated with DES | DES=100% | 1 center in the United States | 2003-2004 | Definite | AST=13%; SAST=66%; LST=21% | DAPT=63% | NR |
| Kimura 2010 (RESTART) (N=611) | R | Patients undergoing PCI with sirolimus-eluting stent implantation (69% STEMI, 23% NSTEMI/UA at presentation) | DES=100% | 543 centers in Japan | 2004-2008 | Definite | EST=53%; LST=17%; VLST=30% | DAPT=55% | Industry |
| Le Feuvre 2008 (n=52) | I | Patients experiencing ST of a BMS or DES | BMS=69%; DES=31% | 1 center in France | 2003-2007 | Definite | EST=73%; LST=13%; VLST=13% | DAPT=79% | NR |
| Mahmoud 2011 (N=113) | P | All patients undergoing PCI at a single institution (85% presenting with STEM) | BMS=23%; DES=77% | 1 center in the Netherlands | 2002-2010 | Definite | EST=52%; LST=25%; VLST=23% | ASA=61%; CLO=50% | NR |
| Wenaweser 2008 (N=192) | I | Patients undergoing SES or PES implantation and developing ST (68% ACS at presentation) | DES=100% | 2 centers in Switzerland and the Netherlands | 2002-2005 | Definite | EST=48%; LST=16%; VLST=69%; | DAPT=56% | Academic |
ACS=acute coronary syndrome; APT=antiplatelet therapy; ASA=aspirin; AST=acute stent thrombosis; BMS=bare metal stent; CLO=clopidogrel; DAPT=dual antiplatelet therapy; DES=drug-eluting stent; ECG=electrocardiogram; EST=early stent thrombosis; I=indeterminate; IVUS=intravascular ultrasound; LST=late stent thrombosis; MI=myocardial infarction; N=number of stent thromboses; NR=not reported; NSTEMI=non-ST-segment-elevation myocardial infarction; P=prospective; PCI=percutaneous coronary intervention; R=retrospective; SAST=sub-acute stent thrombosis; ST=stent thrombosis; STEMI=ST-segment elevation myocardial infarction; TIC=ticlopidine; UA=unstable angina; VLST=very late stent thrombosis
*
Only 23 ST patients analyzed